Cargando…

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy

PURPOSE: Despite the therapeutic success of existing HER2-targeted therapies, tumors respond quite differently to them. This study aimed at figuring out genetic mutation profile of Chinese HER2-positive patients and investigating predictive factors of neoadjuvant anti-HER2 responses. METHODS: We emp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Kai, Liao, Ning, Chen, Bo, Zhang, Guochun, Wang, Yulei, Guo, Liping, Wei, Guangnan, Jia, Minghan, Wen, Lingzhu, Ren, Chongyang, Cao, Li, Mok, Hsiaopei, Li, Cheukfai, Lin, Jiali, Chen, Xiaoqing, Zhang, Zhou, Hou, Ting, Li, Min, Liu, Jing, Balch, Charles M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383038/ https://www.ncbi.nlm.nih.gov/pubmed/32638235 http://dx.doi.org/10.1007/s10549-020-05778-0

Ejemplares similares

Heterogenous and Low Expression of HER2 in Breast Cancer Overcome by DS-8201a in a Heavily Treated Patient: Case Report and Review of the Literature
por: Li, Cheukfai, et al.
Publicado: (2022)

Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status
por: Zhang, Guochun, et al.
Publicado: (2022)

PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing
por: Jia, Minghan, et al.
Publicado: (2021)

Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours
por: Chen, Bo, et al.
Publicado: (2021)

Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients
por: Wen, Lingzhu, et al.
Publicado: (2021)

Spectrum of MAP3K1 mutations in breast cancer is luminal subtype-predominant and related to prognosis
por: Li, Cheukfai, et al.
Publicado: (2022)

Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer
por: Chen, Bo, et al.
Publicado: (2020)

Genomic alteration profile and PD‐L1 expression among different breast cancer subtypes in Chinese population and their correlations
por: Li, Kai, et al.
Publicado: (2022)

Association of Body Mass Index With Somatic Mutations in Breast Cancer
por: Chen, Bo, et al.
Publicado: (2021)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study
por: Sui, Lin, et al.
Publicado: (2023)

Identification of a novel microRNA recurrence-related signature and risk stratification system in breast cancer
por: Lai, Jianguo, et al.
Publicado: (2019)

Comprehensive analysis of autophagy‐related prognostic genes in breast cancer
por: Lai, Jianguo, et al.
Publicado: (2020)

A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
por: Reix, Nathalie, et al.
Publicado: (2016)

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor
por: Liu, Yuanyuan, et al.
Publicado: (2019)

Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer
por: Zhu, Wenzhen, et al.
Publicado: (2020)

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature
por: Lai, Jianguo, et al.
Publicado: (2020)

GSTM1 polymorphism in Oncotype DX assay is a potential predictive factor for taxane-based neoadjuvant chemotherapy in estrogen receptor-positive Chinese breast cancer patients
por: Zhang, Guochun, et al.
Publicado: (2019)

Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors
por: Yeh, Elizabeth S., et al.
Publicado: (2014)

Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program
por: Bilous, Michael, et al.
Publicado: (2012)

HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
por: Tracey, Natasha, et al.
Publicado: (2019)

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
por: Eustace, A. J., et al.
Publicado: (2021)

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
por: Han, Jinil, et al.
Publicado: (2017)

Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis
por: Lewis Phillips, Gail D., et al.
Publicado: (2017)

Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?
por: Sadanandam, Anguraj, et al.
Publicado: (2012)

The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype
por: Tiainen, Satu, et al.
Publicado: (2020)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples
por: Wilson, Timothy R., et al.
Publicado: (2014)

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
por: Perez, Edith A., et al.
Publicado: (2013)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
por: Chen, Wei, et al.
Publicado: (2023)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
por: Hida, Akira I., et al.
Publicado: (2016)

A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells
por: Wu, Yanyuan, et al.
Publicado: (2017)

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
por: Narbe, Ulrik, et al.
Publicado: (2019)

The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer
por: Jääskeläinen, Minna M., et al.
Publicado: (2023)

Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
por: Li, Junjie, et al.
Publicado: (2018)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vsstd5mqcjvk95lpn3d7t3snol